Application of pdcd4 as a therapeutic target for antidepressants and/or anxiolytics drugs
AssigneeShandong University
InventorsLining ZHANG, Yuan LI, Qun WANG, Chun GUO, Faliang ZHU
Life of this patent
Estimating the term…
Abstract
The application of PDCD4 as a drug treatment target for anti-depression and/or anti-anxiety disorders has been proved by experimental research that the increase of PDCD4 is an important factor leading to depression in the process of stress; PDCD4 as a target to inhibit its expression or function can play a good antidepressant role, and has no effect on normal physiological state. Therefore, PDCD4 can be used as a target in the preparation and screening of antidepressant and/or anxiolytic drugs, which has a broad application prospect.
Claims14
A method comprising targeting programmed cell death factor 4 (PDCD4) in the preparation of an antidepressant and/or anxiolytic drug, wherein the drug interferes with or inhibits the expression of a PDCD4 gene, or antagonizes protein function of PDCD4.
An antidepressant and/or anti-anxiety drug, wherein the medicament comprises an effective amount of a drug which interferes with or inhibits the expression of the PDCD4 gene, or a drug which antagonizes the protein function of the PDCD4, and is pharmaceutically acceptable.
A method of screening for antidepressant and/or anxiolytic drugs, comprising steps of screening PDCD4 as a therapeutic target.
A method for screening early susceptible gene of depression and/or anxiety, comprising testing PDCD4 gene expression levels or protein function levels of PDCD4 with clinical diagnostic reagents.
Dependencies are inferred from the claim text.